KB801 disclosure and why it matters for Krystal Biotech stock

Krystal Biotech (KRYS) recently filed a response with the U.S. Patent and Trademark Office related to its KB801 gene therapy for neurotrophic keratitis, sharing new single patient data from a discontinued clinical study.

The company reported complete closure of a persistent corneal epithelial defect in that patient, with no serious safety concerns observed in the study. It also stressed that the observation does not represent trial results or prove KB801 safety or efficacy.

Krystal Biotech's recent KB801 disclosure comes at the same time as index changes that moved the stock from the S&P 600 to the S&P 400 and its biotechnology sub index. The company reported a 1 year total shareholder return of 139.5% and a year to date share price return of 47.5%, indicating strong momentum, although the 1 month share price return was a more modest 2.2%.

If KB801 has caught your eye, it can be useful to see what else is gaining attention in healthcare gene and data driven treatments through 40 healthcare AI stocks

Bulls view Krystal Biotech's index move and KB801 update as support for a premium valuation. Bears focus on concentration risks and early-stage assets. Do the numbers lean closer to optimism or caution as you weigh the stock's pricing?

Most Popular Narrative: 1% Overvalued

The most followed narrative currently pegs Krystal Biotech’s fair value at $361.67, slightly below the last close of $364.23. This frames today’s price as broadly aligned with that view.

The analysts have a consensus price target of $361.67 for Krystal Biotech based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $474.0, and the most bearish reporting a price target of just $241.0.

Want to see what sits behind that fair value for Krystal Biotech? The narrative leans on rapid revenue expansion, rising profit margins and a richer future earnings multiple. Curious how those moving parts are combined into one long term earnings trajectory and discount rate assumption? The full narrative lays out every step of that calculation.

Result: Fair Value of $361.67 (OVERVALUED)

However, there are still clear pressure points for Krystal Biotech, including its heavy reliance on VYJUVEK and the clinical and reimbursement risk around KB801 and other pipeline programs.

Another View on Krystal Biotech’s Valuation

The popular narrative frames Krystal Biotech as about 1% overvalued around $362 per share, yet the Simply Wall St DCF model presents a very different picture. On that math, KRYS at $364.23 sits far below an estimated future cash flow value of $1,080.61, which implies a large valuation gap. Which story seems closer to how you think cash flows will actually play out?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Krystal Biotech for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Krystal Biotech pulled between optimism on its pipeline and concerns around concentration and execution risk, it makes sense to review the full picture now and decide where you stand. You can weigh both sides of that debate by checking the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Krystal Biotech?

If Krystal Biotech has sharpened your focus, do not stop here. Fresh ideas often come from comparing quality, risk and income across a wider watchlist.

• Spot potential mispricings early and review companies in the 49 high quality undervalued stocks that combine quality fundamentals with attractive pricing.
• Prioritise resilience and scan companies in the 83 resilient stocks with low risk scores that score well on balance sheet strength and lower overall risk.
• Aim for staying power and sustainable payouts by checking stocks in the 8 dividend fortresses that focus on income with higher yields.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.